Early pregnancy subclinical hypothyroidism raises risk of reduced thyroid function by over 4x within 5 years postpartum, highlighting need for careful monitoring.

Progression of Gestational Subclinical Hypothyroidism and Hypothyroxinemia to Overt Hypothyroidism After Pregnancy: Pooled Analysis of Data from Two Randomized Controlled Trials
Go to source).
What is Subclinical Hypothyroidism?
Subclinical hypothyroidism, or a change in the levels of thyroid-stimulating hormone (TSH) that isn’t severe enough to cause symptoms, is especially common during pregnancy, affecting as many as 1 in 4 pregnant people. While subclinical hypothyroidism isn’t inherently dangerous, overt hypothyroidism comes with serious symptoms including fatigue, depression, and heart problems.TOP INSIGHT
Higher levels of #thyroid antibodies during #pregnancy increases risk of #hypothyroidism after childbirth. #Autoimmune factors play a role in postpartum thyroid issues. #thyroidhealth
The investigators found that diagnosis of hypothyroxinemia, a deficiency in the thyroid hormone thyroxine, before 21 weeks of pregnancy was not associated with the development of overt hypothyroidism after delivery.
“Studying the long-term associations of test results, as well as the impacts of our interventions, during pregnancy on the health and well-being of mothers and children is a particularly important aspect of clinical research in perinatal medicine,” Varner says.
“While the parent NICHD Maternal-Fetal Medicine Units Network trials from which our data are derived showed no difference in 5-year neurodevelopmental outcomes in children from prenatal treatment of either subclinical hypothyroidism or hypothyroxinemia, our data lend further evidence to the postpartum time period as a time when autoimmune diseases, in this case, hypothyroidism, are more likely to be present.”
Reference:
- Progression of Gestational Subclinical Hypothyroidism and Hypothyroxinemia to Overt Hypothyroidism After Pregnancy: Pooled Analysis of Data from Two Randomized Controlled Trials - (https://www.liebertpub.com/doi/10.1089/thy.2023.0616)
Source-Eurekalert
MEDINDIA




Email










